PBS Growth The changing composition of the PBS PBS Top 10 drugs in transition Shifting sands for industry as generic volume soars The under co-payment market PBS Update 2014-15
Growth in PBS spending was negative in 2014-15, including rebates 16.2% 9.2% 9.1% 9.4% 9.2% 9.0% 5.2% 6.1% 4.3% 3.2% 1.9% -4.5% -3.5% 02-03 03-04 04-05 05-06 06-07 07-08 08-09 09-10 10-11 11-12 12-13 13-14 14-15 Source: PBS Statistics, Department of Health (including revenue)
PBS Growth The changing composition of the PBS PBS Top 10 in transition Shifting sands for industry as generic volume soars The under co-payment market
PBS spending is shifting to highly specialised drugs Growth by category 09-10 to 14-15 $596 $574 $351 $156 -$11 -$259 Concessional General HSD S100 Revenue Total 2014-15 $5,383m $1,505m $1,209m $946m $574m $8,498m* 2009-10 $5,642m $1,516m $858m $350m $49m $8,342m* Source: PBS Statistics, Department of Health (*includes Drs Bag and Safety Net Cards)
PBS Growth The changing composition of the PBS PBS Top 10 drugs in transition Shifting sands for industry as generic volume soars The under co-payment market
PBS Top 10 drugs by cost to Government share of total PBS spending The Top 10 is not what it used to be 25% 19% Source: Department of Health (excluding rebates) 11-12 14-15
In 2014-15, the Government spent almost $830 million less on the 2011-12 PBS Top 10 Drug Brand Treats Govt Cost in 11-12 Govt Cost in 14-15 Atorvastatin LIPITOR Cholesterol $593m $123m 10 Rosuvastatin CRESTOR Cholesterol $359m $215m 2 Ranibizumab LUCENTIS Macular degeneration Adalimumab HUMIRA Rheumatoid arthritis Fluticasone with Salmeterol $307m $157m 7 $198m $312m 1 SERETIDE Asthma $169m $177m 3 Esomeprazole NEXIUM Reflux $168m $174m 5 Olanzapine ZYPREXA Depression $159m $65m 24 Clopidogrel* PLAVIX Blood thinner $133m Etanercept ENBREL Rheumatoid arthritis, etc $127m $163m 6 Tiotropium SPIRIVA COPD $117m $116m 11 TOTALS $2,330m $1,502m Source: PBS Statistics, Department of Health (Section 85 only) * No longer in the top 50 14-15 Rank by Govt Cost
The total cost to Government of the drugs that make up the 2014-15 PBS Top 10 has fallen by almost $250 million in three years largely due to cholesterol lowering medicines Drug Brands Treats Govt Cost in 11-12 Adalimumab HUMIRA Rheumatoid arthritis Govt Cost in 14-15 $198m $312m 4 Rosuvastatin CRESTOR* Cholesterol $359m $215m 2 Fluticasone with Salmeterol SERETIDE Asthma/COPD $169m $177m 5 Aflibercept EYLEA Macular degeneration $174m n/a Esomeprazole NEXIUM* Reflux $168m $174m 6 Etanercept ENBREL Rheumatoid arthritis Ranibizumab LUCENTIS Macular degeneration $127m $163m 9 $307m $157m 3 Insulin Glargine LANTUS Diabetes $105m $145m 8 Fingolimod GILENYA MS $138m n/a Atorvastatin LIPITOR* Cholesterol $593m $123m 1 TOTALS $2,026m $1,778m Source: PBS Statistics, Department of Health (Section 85 only) * Off-patent originator brand 11-12 Ranking by Govt Cost
PBS spending has shifted towards biologics Change in Government cost 11-12 to 14-15 Insulin Glargine $50m Ranibizumab Aflibercept Etanercept -$150m $174m $36m Total Govt cost of 14-15 Top 10 biologics has grown by $224m Adalimumab $114m Fingolomod $138m Fluticasone with Salmeterol Esomeprazole Atorvastatin -$470m $11m $6m Total Govt cost of 14-15 Top 10 small molecules has fallen by $459m Rosuvastatin -$144m Source: PBS Statistics, Department of Health (Section 85 only)
PBS Growth The changing composition of the PBS PBS Top 10 drugs in transformation Shifting sands for industry The under co-payment market
Significant change in company sales performance in the past three years Company PBS Ex-Man sales 11-12 Company PBS Ex-Man sales 14-15 Pfizer $1,140m Pfizer $602m AstraZeneca $862m Novartis $553m Sanofi $447m MSD $348m GSK $293m Alphapharm $272m Abbott/AbbVie $271m Janssen $259m Lilly $249m Apotex $190m Boehringer Ingelheim $184m Aspen $167m Roche $140m NovoNordisk $116m AstraZeneca $509m Novartis $560m AbbVie $359m MSD $337m Sanofi $327m Bayer $309m Janssen $308m GSK $301m Apotex $279m Alphapharm $255m Boehringer Ingelheim $197m NovoNordisk $140m BMS $139m Mundipharma $139m BMS $107m Source: PBS Statistics, Department of Health derived ex-manufacturer sales (Section 85 only)
Generic companies dominated prescription volume in 2014-15 - Market share by PBS prescription - Alphapharm Apotex 13.0% Aspen 9.1% Pfizer 7.3% AstraZeneca 7.2% Sanofi 5.5% Sandoz 5.1% GSK 4.6% MSD 4.1% BI 3.1% Servier 2.5% Fawns and McAllan 2.1% Mundipharma 1.9% Ascent 1.8% Novartis 1.6% Janssen 1.3% Alcon 1.1% Bayer 1.1% Abbott 1.0% Ranbaxy 1.0% Source: PBS Statistics, Department of Health Prescription volume market share (Section 85 only) 11-12 to 13-14 14.9%
PBS Growth The changing composition of the PBS PBS Top 10 drugs in transition Shifting sands for industry as generic volume soars The under co-payment market
A steady increase in the number of PBS prescriptions dispensed under co-payment 72,322,451 79,031,195 62,019,470 12-13 13-14 14-15 Source: PBS Statistics, Department of Health
Cardiovascular scripts continue to move below co-pay as price disclosure hits 11,762,386 12,031,164.00 2,790,301.00 1,362,258 Atorvastatin RAS-acting agents* Source: PBS Statistics, Department of Health * ARBS, ACE inhibitors and direct renin inhibitors 13-14 14-15